HPV的细胞免疫应答研究进展
摘要
与人乳头瘤病毒(HPV)相关的肿瘤免疫疗法需要T细胞调节机制的干预,并与Th1型细胞因子应答的刺激相关。HPV的清除需要细胞免疫参与,但有关HPV清除机制仍不十分清楚。
出处
《中国麻风皮肤病杂志》
2007年第10期884-887,共4页
China Journal of Leprosy and Skin Diseases
参考文献15
-
1Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular immunology. WB Saunders Company, Philadelphia, USA, 2000.
-
2Bontkes HJ, de Gruijl TD, Bijl A, et al. Human papillomavirus type 16 E2 - specific T- helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J General Virol 1999; 80: 2453 - 2459.
-
3Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. New Engl J Med 1998;338:423 - 428.
-
4Scott M, Stites DP, Moscicki AB. Thl cytokine patterns in cervical human papilloma- virus infection. Chn Diag lab Immunol 1999; 6:751 - 755.
-
5Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews 2002;2:342 - 350.
-
6Greslin I, Mougin C, Seilles E. Biologic des infections a papillomavirus Ⅱ Reponse immunitaire. Ann Biol Clin 1998;56:267 - 276.
-
7Mota F, Rayment S, Chong S, et al. The antigen environment in normal and human papillomavirus (HPV) - related premalignant cervical epithelium. Clin Experi Immunol 1999; 116:33- 40.
-
8Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immuno- deficiency viruspositive men and women. Monogr Natl Cancer Inst 1998;23:15 - 20.
-
9Bamard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon - alpha. Virology 1999;259:305 - 313.
-
10Rudolf MP, Small LA, Velders MP, et al. Vaccine delivery and immunosupression in cervical cancer. In: Stem PL, Beverley PCL, Carroll MW (Eds). Cancer Vaccines and Immunotherapy. Cambridge University Press 2000;82- 106.
-
1Finkelman FD,袁雪.蠕虫诱导的细胞因子应答的调节和生物学功能[J].国外医学（寄生虫病分册）,1992,19(2):74-75.
-
2徐云升,郝飞.HPV16型E7抗原表位的研究进展[J].中华皮肤科杂志,2003,36(5):300-302. 被引量：2
-
3舒翠玲.CD28受体分子的研究进展[J].细胞与分子免疫学杂志,1997,13(A02):8-11.
-
4高群.LEEP锥切治疗宫颈上皮内瘤变68例的疗效观察[J].药物与人,2014,27(7):153-154.
-
5张伟.PBK/TOPK在宫颈癌组织中的表达及临床意义[J].中国免疫学杂志,2015,31(12):1688-1691. 被引量：4
-
6周辛波.抗肿瘤药物—PD-1抑制剂[J].临床药物治疗杂志,2015,13(6):92-92. 被引量：11
-
7李长贵.麻疹病毒血凝素和/或融合蛋白DNA疫苗免疫对病毒攻击后细胞因子应答的影响[J].国外医学（预防．诊断．治疗用生物制品分册）,2004,27(4):178-179.
-
8崔利娟,刘峰,杨静静,赵静,王红梅.宫颈上皮内瘤变患者人乳头状瘤病毒感染状况调查[J].中华医院感染学杂志,2016,26(14):3290-3292. 被引量：4
-
9张卓光.重组HPV16融合蛋白疫苗的初免-加强免疫方案的临床前试验[J].国外医学（预防．诊断．治疗用生物制品分册）,2002,25(2):90-90.
-
10张永法,金雪兰,曹敬梅,赵廷存,王辉,宋向凤,毕新岭.成年小鼠中自反应T细胞的清除机制[J].新乡医学院学报,1996,13(2):93-96.
